{"source_content":"请务必阅读正文之后的重要声明部分[Table_Industry]证券研究报告/专题研究报告2021年5月06日医药生物医疗器械板块2020&2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长[Table_Main][Table_Title]评级：增持（维持）分析师：谢木青执业证书编号：S0740518010004Email：xiemq@r.qlzq.com.cn[Table_Profit]基本状况上市公司数380行业总市值(亿元)84,933.61行业流通市值(亿元)59,862.36[Table_QuotePic]行业-市场走势对比公司持有该股票比例[Table_Report]相关报告迈瑞医疗（300760.SZ）：生命信息业务带动高速增长，诊断及影像产品持续恢复-买入（维持）-谢木青-20210429九强生物(300406.SZ)：业绩符合预期，生化血凝增长加速，病理高景气持续-买入（维持）-谢木青/祝嘉琦-20210428安图生物（603658.SH）：疫情影响逐步消除，化学发光、流水线加速装机-买入（维持）-谢木青/祝嘉琦-20210422[Table_Finance]重点公司基本状况简称股价(元)EPSPEPEG评级20202021E2022E2023E20202021E2022E2023E迈瑞医疗4495.486.748.2910.0981.9666.5954.1344.472.98买入健帆生物951.101.441.962.6786.7366.2548.6735.731.83买入九强生物200.190.881.091.35103.6622.3418.1014.600.94买入安图生物1191.622.653.544.5873.6044.9933.6826.031.43买入南微医学2211.962.824.075.52112.8378.2554.1939.981.96买入欧普康视1140.710.991.301.70160.14114.8888.1767.173.73买入备注：截至日期2021/5/6[Table_Summary]投资要点2020年年报收官，医疗器械行业实现爆发式增长，较2019年进一步加速，其中新冠疫情相关品种需求持续旺盛奠定高增长基础，国内疫情常态化后的快速恢复带来增长加速。2020年医疗器械上市公司收入增速60.15%，利润总额增长157.35%，扣非净利润增长189.25%。具体细分子板块来看，2020年扣非增速从高到低排序为低值耗材、体外诊断、医疗设备、高值耗材，与19年相比，低值耗材大幅提速，主要源自防疫防护类产品等的高需求。2021Q1医疗器械行业在抗疫需求延续和常规业务复苏的双重驱动下延续去年的高增长态势，与20Q1相比增长迅速。上市公司收入增速110.11%，利润总额增长264.14%，扣非净利润增长307.21%，一方面得益于疫情产品需求的持续释放，另一方面也和去年低基数有关。细分子板块来看，2021Q1扣非增速从高到低排序为低值耗材、体外诊断、高值耗材、医疗设备，防疫相关的低值耗材、体外诊断板块增长迅猛。低值耗材：新冠疫情区域性爆发，疫情受益品种需求持续旺盛。2020年子版块收入增长135.89%（+119.35%），扣非净利润增长557.66%(+531.92%)，实现爆发式增长，主要系疫情下移液管、离心管等实验室耗疫情订单及手套等抗疫产品需求爆发带动利润规模大幅增长所致。2021Q1子版块收入增长201.32%（+175.81%），扣非净利润增长792.98%(+712.64%)，实现爆发式增长；期间费用率下降明显，为10.92%（-10.44%）；盈利能力大幅提高，毛利率59.33%（+19.85%），净利率41.17%（+26.80%）；全球新冠疫情持续迎来区域性爆发，疫情后病毒检测、疫苗开发进一步释放耗材需求，实验室耗材订单持续增长，价格稳步提升，拉动板块增长；代表公司如拱东医疗（211.65%，扣非增速，下同）、洁特生物（57.59%）、昌红科技（228.52%）以及防护产品如英科医疗（手套，+2881.60%）、蓝帆医疗（手套，+1170.74%）等持续表现高景气。考虑实验室耗材产能短期内持续紧缺，产线扩张较慢，长期来看国产耗材产品质量改善，市占率或进一步提升；同时规模效应和品牌溢价或激发价格持续攀升，未来有望迎来量价齐升的双重增长，我们看好景气度较高的实验室耗材板块，建议重点关注相关优质企业拱东医疗、洁特生物、昌红科技等。体外诊断：新冠业务常态化输出，常规检测持续回稳。2020年子版块收入增长70.16%（+54.43%），扣非利润同比增长265.87%（+264.58%），全年实现高速增长。一方面，高毛利的新冠检测产品+服务贡献业绩增量；另-40%-20%0%20%40%60%80%18-0718-0918-1119-0119-0319-0519-0719-0919-1120-0120-0320-0520-0720-0920-1121-0121-0321-05医药生物(申万)沪深300请务必阅读正文之后的重要声明部分-2-专题研究报告一方面，国内疫情受控下，企业顺利复工复产，医院诊疗量逐步恢复，常规检测业务陆续恢复。2021Q1子版块收入增长149.54%（+142.98%），扣非利润同比增长453.54%（+427.56%），延续高增长趋势；期间费用率下降，为23.51%（-10.42%）；整体盈利能力提升，毛利率62.99%（+9.21%），净利率32.78%（+14.96%）。随着国内疫情防控进入常态化阶段，新冠检测产品及服务成为相关受益股持续性驱动力；同时，国内疫情控制日益完备，企业复工、医院诊疗还将加速恢复，常规检测业务有望实现高增长。综合考虑竞争格局、常规业务恢复进度，我们看好两条投资方向：1）ICL，行业竞争格局清晰，新冠检测量在防控常态化下有望中期保持高位，传统外包持续恢复，建议重点关注金域医学（+1153.48%，扣非增速，下同）、迪安诊断（+15354.74%）；2）化学发光板块，疫情期间头部企业装机持续加速，随着诊疗人次回升，业绩有望加速恢复，建议重点关注安图生物（+102.71%）、迈瑞医疗（+35.35%）、新产业（+50.17%）。医疗设备：海外抗疫需求持续旺盛，医疗新基建拉动新一轮增长。2020年子版块收入增长33.80%（+25.02%），扣非利润同比增长87.35%（+65.54%），整体表现亮眼。医用场景下，国际市场对抗疫设备如呼吸机、红外额温枪等需求持续旺盛带动，企业相关产品销售量维持高位；消费场景下，血糖、血压计等家用器械产品销售从疫情影响之中加速恢复。2021Q1子版块收入增长45.83%（+32.70%），扣非利润同比增长81.45%（+48.99%），整体表现亮眼；期间费用率略降，为26.41%（-4.85%）；盈利能力增强，毛利率51.55%（-0.54%），净利率23.30%（+4.24%）。一方面，海外疫情反复带来国际市场对抗疫设备如呼吸机、监护仪、麻醉机、输注泵等需求持续旺盛带动，企业相关产品将继续受益；另一方面，全球医疗新基建浪潮下订单需求持续增长，相关产品或将持续受益。长期来说，疫情冲击后公卫支出有望大幅提升，医用设备有望受益于医院ICU、呼吸科、传染科、检验科等科室的加速建设；而家用设备持续保持消费升级与智能升级双轮驱动。看好相关优质企业如迈瑞医疗、鱼跃医疗等。高值耗材：受损业务快速恢复，集采影响趋于缓和。2020年子版块收入增长9.75%（-16.16%），扣非利润同比增长25.73%（+10.53%），收入增速主要受上半年疫情影响有所下滑，但利润端仍然保持较高增长。2021Q1子版块收入增长63.21%（+70.81%），扣非利润同比增长91.35%（+92.06%），收入、利润同比均表现较高增长；期间费用率略降，为35.37%（-7.23%）；盈利能力基本维持稳定，毛利率68.61%（-3.09%），净利率28.07%（+3.00%）。随着国内疫情受控，企业复工复产顺利进行，医院门诊、手术量逐步恢复常态，板块将持续复苏。受带量采购悲观预期影响，中短期高值耗材板块可能持续分化，建议短期规避即将带量采购的关节等骨科产品，考虑到高值耗材带量采购规则复杂，一品一规，短期集采风险低的板块可重点关注，长期来说我们继续看好创新能力强的头部企业，如微创医疗、乐普医疗、蓝帆医疗、健帆生物等。投资建议：医疗器械行业当前正处于黄金发展期，我们看好创新驱动下的进口替代和消费类器械持续放量，疫情虽然短期对行业内各企业带来不同影响，但行业长期趋势并未发生改变。我们一方面建议重点关注具备强产品研发能力和技术实力的企业，包括迈瑞医疗、安图生物、南微医学、微创医疗等，另一方面建议重点关注具备强消费属性的产品企业，包括健帆生物、欧普康视、伟思医疗等请务必阅读正文之后的重要声明部分-3-专题研究报告风险提示：产品市场推广不达预期风险，政策变化风险等。请务必阅读正文之后的重要声明部分-4-专题研究报告内容目录医疗器械板块2020年报：抗产品需求旺盛，低值耗材、体外诊断板块增长强劲-5-低值耗材：疫情下口罩、手套带动板块业绩高增长，手套有望迎来量价齐升-7-体外诊断：新冠检测贡献增量，常规业务逐步恢复....................................-8-医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复...................-8-高值耗材：疫情及政策压力下表现稳健，板块持续复苏.............................-9-医疗器械板块2021Q1：海外需求持续提升，国内业务稳步恢复.....................-10-低值耗材：新冠疫情区域性爆发，受益品种需求持续旺盛.......................-11-体外诊断：新冠业务常态化输出，常规检测持续回稳...............................-12-高值耗材：受损业务快速恢复，集采影响趋于缓和..................................-13-医疗设备：海外抗疫需求持续旺盛，医疗新基建拉动新一轮增长............-14-投资建议............................................................................................................-15-图表目录图表1：医疗器械营收累计同比增长表...............................................................-5-图表2：医疗器械营收累计同比增长图...............................................................-5-图表3：医疗器械净利润总额累计同比增长表............................错误!未定义书签。图表4：医疗器械净利润总额累计同比增长图....................................................-5-图表5：医疗器械扣非利润累计同比增长表........................................................-6-图表6：医疗器械扣非利润累计同比增长图........................................................-6-图表7：医疗器械板块2020年期间费用率情况.................................................-6-图表8：医疗器械板块2020年期间财务比率情况..............................................-6-图表9：医疗器械板块2020年毛利率、净利率及经营现金流情况....................-7-图表10：2020年低值耗材板块业绩表现及盈利能力.........................................-7-图表11：2020年体外诊断板块业绩表现及盈利能力.........................................-8-图表12：2020年医疗设备板块业绩表现及盈利能力.........................................-9-图表13：2020年高值耗材板块业绩表现及盈利能力.......................................-10-图表14：A股医疗器械板块2021Q1盈利增长情况.........................................-10-图表15：A股医疗器械板块2021Q1期间费用率情况.....................................-11-图表16：A股医疗器械板块2021Q1期间财务比率情况.................................-11-图表17：A股医疗器械板块2021Q1毛利率、净利率及经营现金流情况........-11-图表18：2021Q1低值耗材板块业绩表现及盈利能力......................................-12-图表19：2021Q1体外诊断板块业绩表现及盈利能力......................................-13-图表20：2021Q1高值耗材板块业绩表现及盈利能力......................................-14-图表21：2021Q1医疗设备板块业绩表现及盈利能力......................................-15-请务必阅读正文之后的重要声明部分-5-专题研究报告医疗器械板块2020年报：抗产品需求旺盛，低值耗材、体外诊断板块增长强劲我们统计了A股医疗器械板块上市公司的2020年年报情况，按照主营业务比重进行划分，将板块分为医疗设备、高值耗材、体外诊断、低值耗材等四个细分子板块，总计87家上市公司。2020年年报收官，医疗器械行业实现爆发式增长，较2019年进一步加速，其中新冠疫情相关品种需求持续旺盛奠定高增长基础，国内疫情常态化后的快速恢复带来增长加速。2020年医疗器械上市公司收入增速60.15%，利润总额增长157.35%，扣非净利润增长189.25%。具体细分子板块来看，2020年扣非增速从高到低排序为低值耗材、体外诊断、医疗设备、高值耗材，与19年相比，体外诊断大幅提速，主要源自抗疫产品（手套、口罩等防护类产品以及离心管等检测类产品）等的高需求。从医疗器械子行业来看，各个子板块分化明显，低值耗材收入增135.89%，扣非净利润增557.66%；体外诊断收入增70.16%，扣非净利润增265.87%；医疗设备收入增33.80%，扣非净利润增87.35%，高值耗材收入增9.75%，扣非净利润增25.73%，均有不错表现。图表1：医疗器械营收累计同比增长表图表2：医疗器械营收累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所图表3：医疗器械净利润总额累计同比增长表图表4：医疗器械净利润总额累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所19A20A20Q121Q1医疗器械14.62%60.15%10.85%110.11%低值耗材16.60%135.89%25.51%201.32%高值耗材25.91%9.75%-7.60%63.21%体外诊断15.73%70.16%6.56%149.54%医疗设备8.78%33.80%13.13%45.83%营业收入-50.00%0.00%50.00%100.00%150.00%200.00%250.00%18Q118H118Q318A19Q119H119Q319A20Q120H120Q320A21Q1医疗器械低值耗材高值耗材体外诊断医疗设备19A20A20Q121Q1医疗器械20.35%157.35%13.00%263.14%低值耗材30.55%503.30%61.84%763.50%高值耗材12.82%21.89%-19.96%82.75%体外诊断7.58%235.87%27.99%358.92%医疗设备32.79%59.51%7.36%78.29%净利润总额-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%700.00%800.00%900.00%18Q118H118Q318A19Q119H119Q319A20Q120H120Q320A21Q1医疗器械低值耗材高值耗材体外诊断医疗设备请务必阅读正文之后的重要声明部分-6-专题研究报告图表5：医疗器械扣非利润累计同比增长表图表6：医疗器械扣非利润累计同比增长图来源：Wind，中泰证券研究所来源：Wind，中泰证券研究所疫情导致销售、管理费用率小幅下降，财务费用稳定。2020年医疗器械板块销售费用率12.99%（-4.96%），管理费用率（含研发费用）11.33%（-2.78%），财务费用率1.08%（+0.61%），销售、管理费用率同比小幅下降预计为疫情下市场推广费、差旅费等减少所致，财务费用较为稳定，微小提升主要系汇率影响所致。图表7：医疗器械板块2020年期间费用率情况来源：wind，中泰证券研究所资产负债率保持稳定，资产周转情况良好。2020年医疗器械板块资产负债率稳步下降，为30.41%（-1.42%）；应收账款周转率5.39次（+1.48次），存货周转率2.76次（+0.11次），资产周转情况良好。图表8：医疗器械板块2020年期间财务比率情况来源：wind，中泰证券研究所盈利能力增强，经营性现金流大幅提升。2020年医疗器械板块毛利率58.11%（+5.78%），净利率26.31%（+9.94%），盈利能力持续增强。其中低值耗材、体外诊断、医疗设备的毛利率、净利率均有一定提升，高值耗材基本保持稳定。板块整体的经营现金流为727.71亿元（+201.60%），同比大幅提升，我们预计主要是防疫产品预付款提升的19A20A20Q121Q1医疗器械14.51%189.25%28.64%307.21%低值耗材25.95%557.66%80.34%792.98%高值耗材15.19%25.73%-0.71%91.35%体外诊断1.29%265.87%25.98%453.54%医疗设备21.81%87.35%32.46%81.45%扣非净利润-100.00%0.00%100.00%200.00%300.00%400.00%500.00%600.00%700.00%800.00%900.00%18Q118H118Q318A19Q119H119Q319A20Q120H120Q320A21Q1医疗器械低值耗材高值耗材体外诊断医疗设备主要子板块20192020同比变化20192020同比变化20192020同比变化医疗器械17.95%12.99%-4.96%14.12%11.33%-2.78%0.46%1.08%0.61%低值耗材13.04%5.99%-7.04%11.34%6.99%-4.34%0.71%1.47%0.76%高值耗材26.77%23.38%-3.39%16.05%16.58%0.53%1.01%0.76%-0.26%体外诊断17.63%14.52%-3.11%15.10%12.11%-2.99%0.93%1.10%0.18%医疗设备16.68%13.66%-3.02%13.67%12.42%-1.25%-0.30%0.72%1.02%销售费用率管理费用率（含研发费用）财务费用率主要子板块20192020同比变化20192020同比变化（次）20192020同比变化（次）医疗器械31.83%30.41%-1.42%3.915.391.482.652.760.11低值耗材32.55%31.39%-1.15%5.189.564.393.474.010.54高值耗材28.80%24.99%-3.81%4.154.430.281.831.74(0.09)体外诊断31.52%30.43%-1.09%2.863.470.612.903.070.17医疗设备34.30%34.26%-0.04%4.777.192.422.652.49(0.15)资产负债率应收账款周转率存货周转率请务必阅读正文之后的重要声明部分-7-专题研究报告原因。图表9：医疗器械板块2020年毛利率、净利率及经营现金流情况来源：wind，中泰证券研究所低值耗材：疫情下口罩、手套带动板块业绩高增长，手套有望迎来量价齐升低值耗材：疫情下口罩、手套个股带动板块业绩高增长。2020年子版块收入增长135.89%（+119.35%），扣非净利润增长557.66%(+531.92%)，实现爆发式增长；期间费用率下降明显，为14.45%（-10.63%）；盈利能力大幅提高，毛利率55.22%（+16.01%），净利率30.64%（+18.70%）。主要系疫情影响下移液管、离心管等实验室耗疫情订单需求爆发增长带动利润规模大幅增长所致，代表公司如拱东医疗（62.79%）、洁特生物（80.81%）、昌红科技（173.23%）表现亮眼，同时防疫产品需求旺盛，生产企业如英科医疗（手套，+4045.04%，扣非增速，下同）、蓝帆医疗（手套，+268.23%）、奥美医疗（口罩，+284.50%）等同样增长迅速。图表10：2020年低值耗材板块业绩表现及盈利能力来源：wind，中泰证券研究所主要子板块20192020同比变化20192020同比变化20192020同比增长医疗器械52.33%58.11%5.78%16.37%26.31%9.94%2412972771201.60%低值耗材39.21%55.22%16.01%11.94%30.64%18.70%342422248549.70%高值耗材72.02%69.76%-2.26%22.59%25.09%2.50%5160641024.21%体外诊断53.09%60.73%7.64%13.71%27.07%13.36%756524923229.48%医疗设备47.87%51.50%3.63%17.35%20.68%3.33%807520088148.76%净利率毛利率经营性现金流（百万元）20192020同比变化20192020同比变化20192020同比变化300677.SZ英科医疗0.95%4045.04%4044.09%25.10%69.03%43.93%8.56%50.64%42.08%603301.SH振德医疗10.15%2275.59%2265.44%32.07%46.97%14.90%8.40%24.52%16.12%300030.SZ阳普医疗-101.67%5871.69%5973.37%43.40%46.81%3.41%4.53%17.68%13.15%002382.SZ蓝帆医疗21.98%268.23%246.24%46.63%64.40%17.77%14.11%22.35%8.24%002950.SZ奥美医疗34.14%284.50%250.36%33.88%41.72%7.83%13.85%30.19%16.34%603880.SH南卫股份7.45%275.58%268.13%21.56%33.87%12.32%5.71%9.14%3.44%603309.SH维力医疗64.31%58.94%-5.37%44.25%43.75%-0.49%12.19%13.54%1.35%600529.SH山东药玻31.44%22.78%-8.66%36.91%33.56%-3.35%15.33%16.47%1.14%603987.SH康德莱16.54%18.66%2.12%37.88%38.58%0.70%9.36%7.67%-1.70%603976.SH正川股份-28.90%-19.03%9.88%27.14%25.55%-1.59%11.72%10.57%-1.15%605369.SH拱东医疗32.48%95.28%62.79%44.42%49.52%5.11%20.54%27.23%6.68%688026.SH洁特生物17.21%98.02%80.81%44.70%46.32%1.61%26.73%23.69%-3.04%300151.SZ昌红科技18.67%191.91%173.23%26.47%35.65%9.18%8.64%15.10%6.47%300981.SZC中红53.71%3006.01%2952.30%18.85%70.83%51.98%7.62%55.74%48.12%603367.SH辰欣药业-1.05%-14.26%-13.21%57.43%57.24%-0.19%12.51%11.94%-0.57%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-8-专题研究报告体外诊断：新冠检测贡献增量，常规业务逐步恢复体外诊断：新冠检测贡献增量，常规业务逐步恢复。2020年子版块收入增长70.16%（+54.43%），扣非利润同比增长265.87%（+264.58%），全年实现高速增长；期间费用率下降，为27.74%（-5.92%）；整体盈利能力提升，毛利率60.73%（+7.64%），净利率27.07%（+13.36%）。一方面，高毛利的新冠检测产品+服务贡献业绩增量；另一方面，国内疫情受控下，企业顺利复工复产，医院诊疗量逐步恢复，常规检测业务陆续恢复。图表11：2020年体外诊断板块业绩表现及盈利能力来源：wind，中泰证券研究所医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械快速恢复医疗设备：医用场景呼吸机、监护仪需求持续旺盛，消费场景家用器械20192020同比变化20192020同比变化20192020同比变化688289.SH圣湘生物560.56%6786.15%6225.59%65.16%79.64%14.48%10.80%54.94%44.13%002030.SZ达安基因-74.73%19912.78%19987.52%49.82%70.76%20.94%8.39%45.85%37.46%688298.SH东方生物21.43%2081.82%2060.39%47.51%79.24%31.74%22.35%51.37%29.02%300676.SZ华大基因-28.36%825.16%853.52%53.56%60.07%6.51%9.87%24.89%15.02%688399.SH硕世生物39.23%907.13%867.90%81.76%77.59%-4.17%29.00%47.11%18.11%002932.SZ明德生物-39.73%1423.15%1462.88%74.32%78.21%3.89%22.92%48.89%25.97%603392.SH万泰生物38.96%273.71%234.75%72.05%81.22%9.17%17.64%28.76%11.11%603882.SH金域医学67.29%357.24%289.95%39.48%46.69%7.21%7.64%18.31%10.68%300639.SZ凯普生物36.03%160.87%124.84%80.59%73.37%-7.22%20.19%26.77%6.58%300244.SZ迪安诊断-17.51%171.97%189.48%32.15%38.22%6.07%4.11%7.54%3.43%300482.SZ万孚生物38.28%59.08%20.80%65.21%69.02%3.81%18.70%22.56%3.86%688389.SH普门科技65.61%44.72%-20.89%60.51%60.87%0.37%23.79%25.99%2.20%300463.SZ迈克生物18.97%49.88%30.91%51.82%53.12%1.30%16.30%21.43%5.14%300298.SZ三诺生物-14.98%-22.39%-7.41%65.14%65.25%0.12%14.10%9.27%-4.82%300685.SZ艾德生物8.30%25.69%17.38%90.37%86.97%-3.40%23.42%24.76%1.33%688393.SH安必平24.35%0.15%-24.20%83.69%79.77%-3.92%20.83%22.57%1.74%603387.SH基蛋生物38.48%-16.56%-55.04%72.79%63.03%-9.76%35.08%27.13%-7.96%300832.SZ新产业11.92%19.36%7.44%79.96%77.18%-2.78%45.95%42.79%-3.16%300318.SZ博晖创新-83.48%-134.08%-50.60%48.39%48.69%0.30%0.40%1.02%0.61%688338.SH赛科希德24.18%1.78%-22.40%59.41%60.13%0.72%30.95%31.11%0.17%300396.SZ迪瑞医疗19.02%-13.31%-32.33%64.44%55.71%-8.73%22.99%28.50%5.51%603658.SH安图生物38.29%-8.35%-46.63%66.57%59.75%-6.82%28.89%25.11%-3.78%300289.SZ利德曼-84.79%-1114.30%-1029.51%54.69%54.31%-0.38%1.22%-10.81%-12.04%300439.SZ美康生物-382.94%-121.17%261.76%34.39%36.85%2.46%-17.87%13.01%30.88%000710.SZ贝瑞基因15.87%-61.03%-76.91%61.13%52.63%-8.50%24.15%13.68%-10.47%300406.SZ九强生物9.37%-61.67%-71.05%68.77%61.49%-7.28%39.44%13.24%-26.20%300642.SZ透景生命18.20%-30.51%-48.71%78.57%66.39%-12.18%35.57%24.62%-10.94%688317.SH之江生物-12.22%1993.02%2005.24%76.12%74.60%-1.52%19.90%45.42%25.51%688468.SH科美诊断44.22%-18.75%-62.96%74.98%72.45%-2.53%30.92%27.98%-2.94%688606.SH奥泰生物26.32%851.18%824.86%62.29%82.25%19.96%32.49%59.81%27.32%688656.SH浩欧博37.33%-29.99%-67.32%68.07%65.56%-2.51%24.64%25.52%0.88%688068.SH热景生物-28.23%310.93%339.17%73.12%63.01%-10.11%16.10%21.82%5.72%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-9-专题研究报告快速恢复。2020年子版块收入增长33.80%（+25.02%），扣非利润同比增长87.35%（+65.54%），整体表现亮眼；期间费用率持续下降，为26.80%（-3.25%）；盈利能力持续提升，毛利率51.50%（3.63%），净利率20.68%（+3.33%）。医用场景下受国内疫情防控及海外疫情反复带来国际市场对抗疫设备如呼吸机、监护仪、红外额温枪、输注泵等需求持续旺盛带动，企业相关产品销售量维持高位；消费场景下，血糖、血压计等家用器械产品销售从疫情影响之中加速恢复。图表12：2020年医疗设备板块业绩表现及盈利能力来源：wind，中泰证券研究所高值耗材：疫情及政策压力下表现稳健，板块持续复苏高值耗材：疫情及政策压力下表现稳健，板块持续复苏。2020年子版块收入增长9.75%（-16.16%），扣非利润同比增长25.73%（+10.53%），收入增速主要受上半年疫情影响有所下滑，但利润端仍然保持较高增长；期间费用率略降，为40.72%（-3.12%）；盈利能力基本维持稳定，毛利率69.76%（-2.26%），净利率25.09%（+2.50%）。随着国内疫情受控，企业复工复产顺利进行，医院诊疗活动恢复常态，相关企业如眼科的爱博医疗（41.22%，扣非增速，下同）、欧普康视（48.60%），心血管支架的心脉医疗（57.37%），以及骨科植入耗材的大博医疗（30.78%）、血液灌流的健帆生物（61.10%）等表现优异。20192020同比变化20192020同比变化20192020同比变化300869.SZ康泰医学16.50%771.01%754.52%47.23%58.25%11.02%19.05%43.78%24.72%600587.SH新华医疗-55.10%-764.62%-709.52%21.23%23.28%2.05%9.82%2.56%-7.27%300206.SZ理邦仪器197.60%433.14%235.54%55.94%59.41%3.47%11.60%28.17%16.57%688301.SH奕瑞科技85.81%132.73%46.92%49.27%51.80%2.53%17.65%28.34%10.69%300314.SZ戴维医疗274.97%149.61%-125.36%53.77%58.64%4.87%17.41%29.64%12.22%002551.SZ尚荣医疗-16.56%223.60%240.16%21.55%30.64%9.10%3.90%7.15%3.25%002223.SZ鱼跃医疗10.15%129.82%119.67%42.21%52.68%10.47%16.23%26.15%9.92%300562.SZ乐心医疗71.58%135.06%63.48%24.27%25.01%0.74%3.52%5.25%1.73%002022.SZ科华生物4.47%258.44%253.97%43.97%58.29%14.32%8.39%16.25%7.87%688139.SH海尔生物202.54%87.88%-114.67%53.63%50.49%-3.14%17.98%27.17%9.19%600055.SH万东医疗8.19%52.25%44.05%46.87%50.37%3.50%17.19%19.50%2.30%300358.SZ楚天科技4.44%613.65%609.21%31.31%33.91%2.60%2.45%5.61%3.16%300760.SZ迈瑞医疗25.04%41.70%16.66%65.24%64.97%-0.27%28.27%31.66%3.39%688580.SH伟思医疗64.88%35.82%-29.06%73.71%73.63%-0.08%31.27%37.97%6.70%300273.SZ和佳医疗-80.64%329.03%409.67%50.33%49.26%-1.06%3.39%6.72%3.33%688358.SH祥生医疗6.87%-6.79%-13.66%60.91%58.58%-2.34%28.43%29.91%1.48%688277.SH天智航-U-13.74%129.10%142.84%84.95%76.99%-7.95%-13.49%-40.08%-26.59%300753.SZ爱朋医疗26.35%6.17%-20.18%70.49%57.44%-13.06%26.96%21.88%-5.07%300633.SZ开立医疗-66.76%-223.46%-156.70%65.28%66.45%1.16%8.10%-3.98%-12.08%688607.SH康众医疗-24.79%90.92%115.70%44.12%43.40%-0.72%20.54%22.15%1.61%688617.SH惠泰医疗84.58%21.30%-63.28%70.82%70.36%-0.46%20.44%23.11%2.66%688626.SH翔宇医疗72.62%52.23%-20.39%66.40%67.75%1.35%30.18%39.61%9.43%002432.SZ九安医疗74.36%-202.39%-276.75%28.79%56.31%27.52%9.41%12.07%2.66%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-10-专题研究报告图表13：2020年高值耗材板块业绩表现及盈利能力来源：wind，中泰证券研究所医疗器械板块2021Q1：海外需求持续提升，国内业务稳步恢复2021Q1医疗器械行业持续去年的高增长态势，与20Q1相比增长迅速。上市公司收入增速110.11%，利润总额增长264.14%，扣非净利润增长307.21%，一方面得益于疫情产品需求的持续释放，另一方面也和去年的低基数有关。具体细分子板块来看，2021Q1扣非增速从高到低排序为低值耗材、体外诊断、高值耗材、医疗设备，防疫相关的低值耗材、体外诊断板块增长迅猛。从医疗器械子行业来看，各个子板块分化明显，低值耗材收入增201.32%，扣非净利润增792.98%；体外诊断收入增149.54%，扣非净利润增453.54%；高值耗材收入增63.21%，扣非净利润增91.35%，医疗设备收入增45.83%，扣非净利润增81.45%，各板块增长态势显著。图表14：A股医疗器械板块2021Q1盈利增长情况来源：wind，中泰证券研究所20192020同比变化20192020同比变化20192020同比变化300246.SZ宝莱特10.96%441.37%430.42%39.77%46.72%6.95%7.83%24.80%16.96%300238.SZ冠昊生物-2906.88%-107.21%2799.67%67.70%72.53%4.83%-106.27%10.66%116.93%300453.SZ三鑫医疗49.08%87.54%38.47%34.40%32.38%-2.02%8.55%12.30%3.75%300529.SZ健帆生物48.19%61.10%12.91%86.21%85.24%-0.98%39.87%44.87%5.00%688016.SH心脉医疗44.92%57.37%12.45%79.35%79.10%-0.24%42.48%45.64%3.16%688050.SH爱博医疗582.80%41.22%-541.57%85.69%83.91%-1.78%34.16%35.36%1.20%300595.SZ欧普康视40.88%48.60%7.71%78.41%78.54%0.13%47.44%49.77%2.33%002901.SZ大博医疗30.23%30.78%0.55%85.61%85.87%0.26%37.02%38.17%1.15%300003.SZ乐普医疗18.21%13.87%-4.33%72.23%66.99%-5.24%22.13%22.42%0.28%300653.SZ正海生物24.96%5.50%-19.46%93.12%92.23%-0.89%38.38%40.35%1.97%688085.SH三友医疗65.50%7.65%-57.86%91.26%90.87%-0.39%27.61%30.37%2.76%688198.SH佰仁医疗22.59%-30.30%-52.89%91.04%88.89%-2.15%43.20%31.07%-12.13%300326.SZ凯利泰94.06%-157.47%-251.53%65.74%66.61%0.86%24.73%-11.92%-36.65%688029.SH南微医学58.02%-23.25%-81.27%65.79%66.03%0.23%23.22%19.66%-3.56%688013.SH天臣医疗93.10%-29.05%-122.15%60.04%58.32%-1.72%24.32%21.40%-2.92%688108.SH赛诺医疗-0.07%-87.36%-87.29%82.93%79.90%-3.03%20.65%6.87%-13.79%688677.SH海泰新光26.55%22.87%-3.67%58.37%63.68%5.32%28.45%35.01%6.57%688366.SH昊海生科-4.96%-42.25%-37.30%77.31%74.93%-2.38%23.11%17.27%-5.84%证券代码证券简称扣非净利润增速毛利率净利率20Q121Q1增速变化20Q121Q1增速变化医疗器械10.85%110.11%99.26%28.64%307.21%278.58%低值耗材25.51%201.32%175.81%80.34%792.98%712.64%高值耗材-7.60%63.21%70.81%-0.71%91.35%92.06%体外诊断6.56%149.54%142.98%25.98%453.54%427.56%医疗设备13.13%45.83%32.70%32.46%81.45%48.99%扣除非经常性损益的净利润增速主要子板块营业收入增速请务必阅读正文之后的重要声明部分-11-专题研究报告2021Q1医疗器械板块销售费用率、管理费用率持续下降，财务费用保持稳定，延续去年态势。2021Q1医疗器械板块销售费用率11.69%（-4.96%），管理费用率（含研发费用）10.05%（-4.82%），财务费用率0.10%（-0.11%），销售、管理费用率同比小幅下降预计为疫情下市场推广费、差旅费等减少所致。图表15：A股医疗器械板块2021Q1期间费用率情况来源：wind，中泰证券研究所资产负债率稳步下降，资产周转情况持续提升。2021Q1医疗器械板块资产负债率27.94%（-4.32%），延续下降态势；应收账款周转率1.43次（+0.50次），存货周转率0.70次（+0.13次），资产周转情况良好。图表16：A股医疗器械板块2021Q1期间财务比率情况来源：wind，中泰证券研究所盈利能力增强，经营性现金流大幅提升。2021Q1医疗器械板块毛利率60.29%（+6.93%），净利率32.91%（+13.97%），盈利能力增强。其中低值耗材、体外诊断、医疗设备的毛利率、净利率提升明显，高值耗材基本保持稳定。板块整体的经营现金流为141.21亿元（+162.72%），同比大幅提升，我们预计主要是防疫产品预付款提升的原因。图表17：A股医疗器械板块2021Q1毛利率、净利率及经营现金流情况来源：wind，中泰证券研究所低值耗材：新冠疫情区域性爆发，受益品种需求持续旺盛低值耗材：新冠疫情区域性爆发，疫情受益品种需求持续旺盛。2021Q1主要子板块20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比变化医疗器械16.66%11.69%-4.96%14.87%10.05%-4.82%0.21%0.10%-0.11%低值耗材10.91%4.64%-6.27%10.45%6.03%-4.42%0.00%0.25%0.25%高值耗材25.42%20.69%-4.73%16.98%14.54%-2.44%0.19%0.13%-0.06%体外诊断17.04%13.58%-3.46%16.08%9.88%-6.20%0.81%0.05%-0.76%医疗设备16.14%13.30%-2.84%15.28%13.07%-2.21%-0.15%0.05%0.20%销售费用率管理费用率（含研发费用）财务费用率主要子板块20Q121Q1同比变化20Q121Q1同比变化（次）20Q121Q1同比变化（次）医疗器械32.25%27.94%-4.32%0.931.430.500.570.700.13低值耗材33.16%26.43%-6.74%1.402.310.900.861.050.19高值耗材28.01%25.46%-2.56%0.821.230.400.350.510.15体外诊断32.96%28.10%-4.86%0.610.960.350.580.770.19医疗设备34.20%31.88%-2.31%1.261.830.570.570.610.04资产负债率应收账款周转率存货周转率主要子板块20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比增长医疗器械53.36%60.29%6.93%19.04%32.91%13.87%537514121162.72%低值耗材39.48%59.33%19.85%14.37%41.17%26.80%12835390320.22%高值耗材71.71%68.61%-3.09%25.06%28.07%3.00%2822074635.42%体外诊断53.78%62.99%9.21%17.83%32.78%14.96%11584240266.10%医疗设备52.09%51.55%-0.54%19.06%23.30%4.24%24732385-3.56%净利率毛利率经营性现金流（百万元）请务必阅读正文之后的重要声明部分-12-专题研究报告子版块收入增长201.32%（+175.81%），扣非净利润增长792.98%(+712.64%)，实现爆发式增长；期间费用率下降明显，为10.92%（-10.44%）；盈利能力大幅提高，毛利率59.33%（+19.85%），净利率41.17%（+26.80%）；全球新冠疫情持续迎来区域性爆发，疫情后病毒检测、疫苗开发进一步释放耗材需求，实验室耗材订单持续增长，价格稳步提升，拉动板块高增长；代表公司如拱东医疗（211.65%，扣非增速，下同）、洁特生物（57.59%）、昌红科技（228.52%）以及防护防疫产品如英科医疗（手套，+2881.60%）、蓝帆医疗（手套，+1170.74%）等持续表现高景气。考虑实验室耗材产能短期内将持续面临供不应求的紧缺状态，产线扩张相对较慢，长期来看国产耗材产品质量改善，市占率或进一步提升；同时产品价格在规模效应和品牌溢价的加持下或持续攀升，未来有望迎来量价齐升的双重增长，我们看好景气度较高的实验室耗材板块，建议重点关注相关优质企业拱东医疗、洁特生物、昌红科技等。图表18：2021Q1低值耗材板块业绩表现及盈利能力来源：wind，中泰证券研究所体外诊断：新冠业务常态化输出，常规检测持续回稳体外诊断：新冠业务常态化输出，常规检测持续回稳。2021Q1子版块收入增长149.54%（+142.98%），扣非利润同比增长453.54%（+427.56%），延续高增长趋势；期间费用率下降，为23.51%（-10.42%）；整体盈利能力提升，毛利率62.99%（+9.21%），净利率32.78%（+14.96%）。随着国内疫情防控进入常态化阶段，新冠检测产品及服务成为相关受益股持续性驱动力；同时，国内疫情控制日益完备，企业复工、医院诊疗还将加速恢复，常规检测业务有望实现高增长。综合考虑竞争格局、常规业务恢复进度，我们看好两条投资方向：1）ICL，行业竞争格局清晰，新冠检测量在防控常态化下有望中期保持高位，传统外包持续恢复，建议重点关注金域医学（+1153.48%，扣非增速，下同）、迪安诊断（+15354.74%）；2）化学发光板块，疫情期间头部企业装机持续加速，随着诊疗人次回升，业绩有望加速恢复，建议重点关注安图生20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比变化300677.SZ英科医疗276.05%2881.60%2605.55%34.07%70.48%36.40%16.71%55.47%38.76%603301.SH振德医疗912.34%171.46%-740.89%42.08%37.68%-4.40%12.12%12.74%0.63%300030.SZ阳普医疗-379.67%232.87%612.55%47.09%46.50%-0.59%7.45%14.36%6.91%002382.SZ蓝帆医疗63.94%1170.74%1106.80%41.30%68.83%27.53%16.14%54.26%38.13%002950.SZ奥美医疗107.86%11.45%-96.41%35.74%31.02%-4.72%15.26%14.17%-1.09%603880.SH南卫股份1.26%3.06%1.80%25.07%23.85%-1.22%9.39%6.44%-2.95%603309.SH维力医疗-15.04%44.48%59.52%42.16%42.54%0.38%5.06%10.32%5.27%600529.SH山东药玻29.93%13.51%-16.42%35.57%27.55%-8.01%17.87%16.87%-1.00%603987.SH康德莱0.89%46.26%45.37%35.38%36.51%1.13%6.53%6.76%0.23%603976.SH正川股份-22.13%-6.38%15.75%26.14%26.32%0.18%13.13%12.72%-0.40%605369.SH拱东医疗-211.65%-46.06%49.96%3.90%23.33%30.29%6.95%688026.SH洁特生物1066.56%57.59%-1008.97%57.59%44.05%-13.53%44.95%27.62%-17.33%300151.SZ昌红科技46.06%228.52%182.45%21.39%32.98%11.59%9.73%14.46%4.73%300981.SZC中红-2629.05%-25.06%74.79%49.72%16.73%61.69%44.96%603367.SH辰欣药业-20.02%4.63%24.65%58.61%59.44%0.83%12.88%12.44%-0.44%扣非净利润增速毛利率净利率证券代码证券简称请务必阅读正文之后的重要声明部分-13-专题研究报告物（+102.71%）、迈瑞医疗（+35.35%）、新产业（+50.17%）。图表19：2021Q1体外诊断板块业绩表现及盈利能力来源：wind，中泰证券研究所高值耗材：受损业务快速恢复，集采影响趋于缓和高值耗材：受损业务快速恢复，集采影响趋于缓和。2021Q1子版块收入增长63.21%（+70.81%），扣非利润同比增长91.35%（+92.06%），收入、利润同比均表现较高增长；期间费用率略降，为35.37%（-7.23%）；盈利能力基本维持稳定，毛利率68.61%（-3.09%），净利率28.07%（+3.00%）。随着国内疫情受控，企业复工复产顺利进行，医院门诊、手术量恢复常态，板块加速恢复，归母净利润提速明显，如眼科的爱博医疗（966.86%，扣非增速，下同）、欧普康视（235.76%），心血管支架的心脉医疗（94.25%）、乐普医疗（81.76%），以及骨科植入耗材的大博医疗（80.43%）、三友医疗（103.78%）、凯利泰（21.51%）和血液灌流的健帆生物（45.07%）等。国家级集采引领高值耗材全国带量采购进程，看好创新能力强的头部企业。国家级冠脉支架、骨科耗材集采出台为其他品类的国家级集采奠定实施基础，起到示范效应。从规则上看，头部企业可通过降价保存量求增量来扩大市场份额，有望相对受益。受带量采购悲观预期影响，中短20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比变化688289.SH圣湘生物3144.99%209.63%-2935.36%81.09%73.82%-7.27%48.32%53.50%5.18%002030.SZ达安基因653.94%517.41%-136.54%56.55%75.95%19.40%31.65%48.23%16.58%688298.SH东方生物-2660.48%-63.24%75.32%12.08%39.79%53.06%13.27%300676.SZ华大基因29.11%369.01%339.90%56.12%63.56%7.44%17.70%33.58%15.88%688399.SH硕世生物-303.86%-88.11%73.62%-14.49%51.70%45.23%-6.47%002932.SZ明德生物-83.29%13474.48%13557.77%70.84%76.66%5.82%6.81%50.41%43.60%603392.SH万泰生物58.97%395.73%336.76%71.60%84.39%12.78%22.66%35.10%12.44%603882.SH金域医学11.96%1153.48%1141.52%37.24%47.10%9.86%4.09%20.09%15.99%300639.SZ凯普生物17.60%826.50%808.89%75.43%65.95%-9.48%13.18%28.21%15.03%300244.SZ迪安诊断-96.89%15354.74%15451.63%28.98%38.02%9.03%0.43%11.80%11.37%300482.SZ万孚生物38.74%48.61%9.87%67.39%70.50%3.11%17.74%22.31%4.58%688389.SH普门科技-50.53%-59.69%64.12%4.42%30.83%32.84%2.00%300463.SZ迈克生物-34.19%298.37%332.56%49.92%60.28%10.36%14.56%29.30%14.74%300298.SZ三诺生物37.79%-39.14%-76.93%66.74%65.98%-0.77%15.02%8.94%-6.08%300685.SZ艾德生物-47.56%183.25%230.81%87.19%82.56%-4.63%28.58%25.00%-3.59%688393.SH安必平-41.51%145.82%187.32%81.44%77.57%-3.87%25.69%26.80%1.11%603387.SH基蛋生物-45.10%75.59%120.69%66.30%62.45%-3.85%29.19%22.70%-6.48%300832.SZ新产业-22.10%50.17%72.27%70.46%70.99%0.53%38.35%31.58%-6.77%300318.SZ博晖创新104.73%-16.80%-121.53%41.05%42.61%1.56%-9.64%-6.58%3.06%688338.SH赛科希德---58.11%61.63%3.52%10.99%38.26%27.26%300396.SZ迪瑞医疗-21.80%53.73%75.53%63.24%55.60%-7.65%21.95%29.42%7.48%603658.SH安图生物-29.36%102.71%132.07%57.91%57.46%-0.45%16.92%20.99%4.07%300289.SZ利德曼-367.52%-138.67%228.85%46.60%54.05%7.45%-27.71%5.42%33.13%300439.SZ美康生物-91.42%1226.73%1318.14%33.83%43.87%10.05%37.56%14.22%-23.34%000710.SZ贝瑞基因-14.24%-66.02%-51.78%55.43%48.81%-6.62%16.86%6.34%-10.52%300406.SZ九强生物-72.67%574.21%646.87%61.07%70.04%8.97%11.30%30.02%18.71%300642.SZ透景生命-296.72%-179.38%117.34%61.22%68.78%7.56%-65.95%19.39%85.35%688317.SH之江生物-223.36%-79.20%72.12%-7.08%45.17%48.19%3.02%688068.SH热景生物-122.03%124996.44%125118.46%75.63%66.14%-9.49%1.34%48.99%47.65%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-14-专题研究报告期高值耗材板块可能持续分化，建议短期规避即将带量采购的关节等骨科产品，考虑到高值耗材带量采购规则复杂，一品一规，短期集采风险低的板块可重点关注，长期来说我们继续看好创新能力强的头部企业，如微创医疗、乐普医疗、蓝帆医疗、健帆生物等。图表20：2021Q1高值耗材板块业绩表现及盈利能力来源：wind，中泰证券研究所医疗设备：海外抗疫需求持续旺盛，医疗新基建拉动新一轮增长医疗设备：抗疫需求持续旺盛，医疗新基建拉动新一轮增长。2021Q1子版块收入增长45.83%（+32.70%），扣非利润同比增长81.45%（+48.99%），整体表现亮眼；期间费用率略降，为26.41%（-4.85%）；盈利能力增强，毛利率51.55%（-0.54%），净利率23.30%（+4.24%）。一方面，海外疫情反复带来国际市场对抗疫设备如呼吸机、监护仪、麻醉机、输注泵等需求持续旺盛带动，企业相关产品将继续受益；另一方面，全球医疗新基建浪潮下订单需求持续增长，相关产品或将持续受益。长期来说，疫情冲击后公卫支出有望大幅提升，医用设备有望受益于医院ICU、呼吸科、传染科、检验科等科室的加速建设；而家用设备持续保持消费升级与智能升级双轮驱动。看好相关优质企业如迈瑞医疗、鱼跃医疗等。20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比变化300246.SZ宝莱特182.12%-41.14%-223.25%43.99%34.75%-9.24%18.28%10.14%-8.14%300238.SZ冠昊生物-7656.71%83.58%7740.28%72.17%77.33%5.16%12.37%14.21%1.83%300453.SZ三鑫医疗136.56%216.62%80.06%35.08%32.67%-2.41%7.05%13.83%6.78%300529.SZ健帆生物55.35%45.07%-10.28%85.74%85.23%-0.51%48.68%48.94%0.26%688016.SH心脉医疗-94.25%-79.20%80.07%0.87%59.96%51.50%-8.47%688050.SH爱博医疗-82.08%966.86%1048.93%85.13%83.08%-2.04%13.03%42.66%29.63%300595.SZ欧普康视-26.18%235.76%261.95%77.63%77.80%0.17%36.52%48.13%11.61%002901.SZ大博医疗-6.62%80.43%87.05%87.02%86.55%-0.47%38.73%34.82%-3.91%300003.SZ乐普医疗-9.79%81.76%91.55%73.69%64.89%-8.80%23.03%26.41%3.38%300653.SZ正海生物-34.60%147.21%181.81%94.37%91.59%-2.79%43.28%43.08%-0.20%688085.SH三友医疗-103.78%-88.95%89.55%0.60%23.98%25.34%1.36%688198.SH佰仁医疗--1.57%-89.45%89.10%-0.36%37.88%16.96%-20.92%300326.SZ凯利泰-37.57%21.51%59.08%59.45%58.86%-0.60%22.31%17.88%-4.43%688029.SH南微医学-51.75%-66.18%66.34%0.16%19.20%16.99%-2.21%688013.SH天臣医疗---59.17%58.92%-0.25%19.67%28.23%8.56%688108.SH赛诺医疗-71.14%-739.40%-668.26%80.00%62.86%-17.13%10.92%-149.03%-159.95%688677.SH海泰新光---65.72%67.95%2.23%42.87%38.91%-3.96%688366.SH昊海生科-152.72%-360.45%-207.72%75.70%74.77%-0.93%-16.18%25.35%41.53%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-15-专题研究报告图表21：2021Q1医疗设备板块业绩表现及盈利能力来源：wind，中泰证券研究所投资建议投资建议：医疗器械行业当前正处于黄金发展期，我们看好创新驱动下的进口替代和消费类器械持续放量，疫情虽然短期对行业内各企业带来不同影响，但行业长期趋势并未发生改变。我们一方面建议重点关注具备强产品研发能力和技术实力的企业，包括迈瑞医疗、安图生物、南微医学、微创医疗等，另一方面建议重点关注具备强消费属性的产品企业，包括健帆生物、欧普康视、伟思医疗等风险提示：产品市场推广不达预期风险；政策变化风险；行业数据进行了一定的筛选和划分，存在与行业实际情况偏差风险等。20Q121Q1同比变化20Q121Q1同比变化20Q121Q1同比变化600587.SH新华医疗16.10%440.22%424.12%23.01%24.75%1.74%1.93%5.82%3.88%300206.SZ理邦仪器140.23%67.25%-72.98%58.14%56.63%-1.52%22.63%24.46%1.83%300314.SZ戴维医疗77.39%49.24%-28.15%51.76%59.78%8.01%19.02%23.15%4.13%002551.SZ尚荣医疗51.31%24.28%-27.03%25.53%34.30%8.77%11.34%9.45%-1.89%002223.SZ鱼跃医疗53.29%20.09%-33.20%53.12%51.86%-1.26%27.51%27.64%0.13%300562.SZ乐心医疗128.95%200.72%71.78%24.64%19.93%-4.71%3.15%3.55%0.40%002022.SZ科华生物-3.85%636.54%640.39%48.43%61.09%12.66%9.32%23.55%14.23%688139.SH海尔生物105.93%99.43%-6.50%50.17%50.22%0.05%25.96%101.50%75.54%600055.SH万东医疗2584.66%-2.59%-2587.26%58.23%51.44%-6.79%20.27%20.42%0.14%300358.SZ楚天科技-4567.36%-392.28%4175.08%33.88%39.56%5.67%-10.37%9.24%19.61%300760.SZ迈瑞医疗25.53%35.35%9.82%64.52%65.03%0.51%27.70%29.67%1.97%688580.SH伟思医疗-8.73%72.51%81.25%73.41%73.28%-0.14%29.79%39.00%9.21%300273.SZ和佳医疗-168.74%-173.94%-5.20%52.42%51.50%-0.92%-23.37%11.38%34.75%688277.SH天智航-U-15.66%47.27%62.93%63.51%75.04%11.54%-62.27%-108.61%-46.34%300753.SZ爱朋医疗-72.46%390.58%463.04%79.19%61.29%-17.90%23.89%18.82%-5.06%300633.SZ开立医疗-4262.87%-242.32%4020.55%63.37%62.22%-1.16%-3.52%12.82%16.35%688626.SH翔宇医疗---66.45%69.63%3.18%31.74%33.89%2.14%002432.SZ九安医疗-232.09%-95.90%136.19%45.16%38.25%-6.92%15.25%11.81%-3.45%证券代码证券简称扣非净利润增速毛利率净利率请务必阅读正文之后的重要声明部分-16-专题研究报告投资评级说明：评级说明股票评级买入预期未来6~12个月内相对同期基准指数涨幅在15%以上增持预期未来6~12个月内相对同期基准指数涨幅在5%~15%之间持有预期未来6~12个月内相对同期基准指数涨幅在-10%~+5%之间减持预期未来6~12个月内相对同期基准指数跌幅在10%以上行业评级增持预期未来6~12个月内对同期基准指数涨幅在10%以上中性预期未来6~12个月内对同期基准指数涨幅在-10%~+10%之间减持预期未来6~12个月内对同期基准指数跌幅在10%以上备注：评级标准为报告发布日后的6~12个月内公司股价（或行业指数）相对同期基准指数的相对市场表现。其中A股市场以沪深300指数为基准；新三板市场以三板成指（针对协议转让标的）或三板做市指数（针对做市转让标的）为基准；香港市场以摩根士丹利中国指数为基准，美股市场以标普500指数或纳斯达克综合指数为基准（另有说明的除外）。重要声明：中泰证券股份有限公司（以下简称“本公司”）具有中国证券监督管理委员会许可的证券投资咨询业务资格。本报告仅供本公司的客户使用。本公司不会因接收人收到本报告而视其为客户。本报告基于本公司及其研究人员认为可信的公开资料或实地调研资料，反映了作者的研究观点，力求独立、客观和公正，结论不受任何第三方的授意或影响。但本公司及其研究人员对这些信息的准确性和完整性不作任何保证，且本报告中的资料、意见、预测均反映报告初次公开发布时的判断，可能会随时调整。本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告所载的资料、工具、意见、信息及推测只提供给客户作参考之用，不构成任何投资、法律、会计或税务的最终操作建议，本公司不就报告中的内容对最终操作建议做出任何担保。本报告中所指的投资及服务可能不适合个别客户，不构成客户私人咨询建议。市场有风险，投资需谨慎。在任何情况下，本公司不对任何人因使用本报告中的任何内容所引致的任何损失负任何责任。投资者应注意，在法律允许的情况下，本公司及其本公司的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。本公司及其本公司的关联机构或个人可能在本报告公开发布之前已经使用或了解其中的信息。本报告版权归“中泰证券股份有限公司”所有。未经事先本公司书面授权，任何人不得对本报告进行任何形式的发布、复制。如引用、刊发，需注明出处为“中泰证券研究所”，且不得对本报告进行有悖原意的删节或修改。","data":[{"id":"1","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"利润总额增长264.14%","content_offset":["1177","1190"],"indicators":[{"indicator_name":"利润总额同比","indicator_value":["264.14%","1183","1190"],"indicator_element":{"时间":["20Q1","1150","1154"],"行业":["医疗器械","1112","1116"],"区域":["国内","2150","2152"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"低值耗材：新冠疫情区域性爆发，疫情受益品种需求持续旺盛。2020年子版块收入增长135.89%（+119.35%）","content_offset":["1305","1362"],"indicators":[{"indicator_name":"营业收入","indicator_value":["135.89%","1345","1352"],"indicator_element":{"时间":["2020年","1333","1338"],"行业":["低值耗材","1305","1309"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"低值耗材：新冠疫情区域性爆发，疫情受益品种需求持续旺盛。2020年子版块收入增长135.89%（+119.35%）","content_offset":["1305","1362"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+119.35%","1353","1361"],"indicator_element":{"时间":["2020年","1333","1338"],"行业":["低值耗材","1305","1309"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长201.32%（+175.81%）","content_offset":["1443","1473"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["201.32%","1456","1463"],"indicator_element":{"时间":["2021Q1","1443","1449"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长201.32%（+175.81%）","content_offset":["1443","1473"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+175.81%","1464","1472"],"indicator_element":{"时间":["2021Q1","1443","1449"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率59.33%（+19.85%）","content_offset":["1543","1561"],"indicators":[{"indicator_name":"毛利率","indicator_value":["59.33%","1546","1552"],"indicator_element":{"时间":["2021Q1","1443","1449"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率59.33%（+19.85%）","content_offset":["1543","1561"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+19.85%","1553","1560"],"indicator_element":{"时间":["2021Q1","1443","1449"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率41.17%（+26.80%）","content_offset":["1562","1580"],"indicators":[{"indicator_name":"净利率","indicator_value":["41.17%","1565","1571"],"indicator_element":{"时间":["2021Q1","2188","2194"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率41.17%（+26.80%）","content_offset":["1562","1580"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+26.80%","1572","1579"],"indicator_element":{"时间":["2021Q1","2188","2194"],"行业":["低值耗材","3803","3807"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长70.16%（+54.43%）","content_offset":["1908","1935"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["70.16%","1920","1926"],"indicator_element":{"时间":["2020年","1908","1913"],"行业":["体外诊断","1884","1888"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长70.16%（+54.43%）","content_offset":["1908","1935"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+54.43%","1927","1934"],"indicator_element":{"时间":["2020年","1908","1913"],"行业":["体外诊断","1884","1888"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长149.54%（+142.98%）","content_offset":["2188","2218"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["149.54%","2201","2208"],"indicator_element":{"时间":["2021Q1","2188","2194"],"行业":["体外诊断","3808","3812"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长149.54%（+142.98%）","content_offset":["2188","2218"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+142.98%","2209","2217"],"indicator_element":{"时间":["2021Q1","2188","2194"],"行业":["体外诊断","3808","3812"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率62.99%（+9.21%））","content_offset":["-1","-1"],"indicators":[{"indicator_name":"毛利率","indicator_value":["62.99%","2","8"],"indicator_element":{"时间":["2021Q1","70","76"],"行业":["体外诊断","1058","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率62.99%（+9.21%））","content_offset":["-1","-1"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+9.21%","9","15"],"indicator_element":{"时间":["2021Q1","70","76"],"行业":["体外诊断","1058","1062"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率32.78%（+14.96%）","content_offset":["2305","2323"],"indicators":[{"indicator_name":"净利率","indicator_value":["32.78%","2308","2314"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["体外诊断","3808","3812"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率32.78%（+14.96%）","content_offset":["2305","2323"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+14.96%","2315","2322"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["体外诊断","3808","3812"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长33.80%（+25.02%）","content_offset":["2648","2675"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["33.80%","2660","2666"],"indicator_element":{"时间":["2020年","2648","2653"],"行业":["医疗设备","2619","2623"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长33.80%（+25.02%）","content_offset":["2648","2675"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+25.02%","2667","2674"],"indicator_element":{"时间":["2020年","2648","2653"],"行业":["医疗设备","2619","2623"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长45.83%（+32.70%）","content_offset":["2789","2817"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["45.83%","2802","2808"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长45.83%（+32.70%）","content_offset":["2789","2817"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+32.70%","2809","2816"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率51.55%（-0.54%）","content_offset":["2880","2897"],"indicators":[{"indicator_name":"毛利率","indicator_value":["51.55%","2883","2889"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率51.55%（-0.54%）","content_offset":["2880","2897"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["-0.54%","2890","2896"],"indicator_element":{"时间":["2021Q1","2789","2795"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率23.30%（+4.24%）","content_offset":["2898","2915"],"indicators":[{"indicator_name":"净利率","indicator_value":["23.30%","2901","2907"],"indicator_element":{"时间":["2021Q1","3216","3222"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率23.30%（+4.24%）","content_offset":["2898","2915"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+4.24%","2908","2914"],"indicator_element":{"时间":["2021Q1","3216","3222"],"行业":["医疗设备","3918","3922"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长9.75%（-16.16%）","content_offset":["3133","3159"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["9.75%","3145","3150"],"indicator_element":{"时间":["2020年","3133","3138"],"行业":["高值耗材","3110","3114"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长9.75%（-16.16%）","content_offset":["3133","3159"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-16.16%","3151","3158"],"indicator_element":{"时间":["2020年","3133","3138"],"行业":["高值耗材","3110","3114"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长63.21%（+70.81%）","content_offset":["3216","3244"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["63.21%","3229","3235"],"indicator_element":{"时间":["2021Q1","3216","3222"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1子版块收入增长63.21%（+70.81%）","content_offset":["3216","3244"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+70.81%","3236","3243"],"indicator_element":{"时间":["2021Q1","3216","3222"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率68.61%（-3.09%）","content_offset":["3319","3336"],"indicators":[{"indicator_name":"毛利率","indicator_value":["68.61%","3322","3328"],"indicator_element":{"时间":["2021Q1","4037","4043"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率68.61%（-3.09%）","content_offset":["3319","3336"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["-3.09%","3329","3335"],"indicator_element":{"时间":["2021Q1","4037","4043"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率28.07%（+3.00%）","content_offset":["3337","3354"],"indicators":[{"indicator_name":"净利率","indicator_value":["28.07%","3340","3346"],"indicator_element":{"时间":["2021Q1","4037","4043"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率28.07%（+3.00%）","content_offset":["3337","3354"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+3.00%","3347","3353"],"indicator_element":{"时间":["2021Q1","4037","4043"],"行业":["高值耗材","3413","3417"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"低值耗材收入增135.89%","content_offset":["6269","6283"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["135.89%","6276","6283"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["低值耗材","6269","6273"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"体外诊断收入增70.16%","content_offset":["6298","6311"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["70.16%","6305","6311"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["体外诊断","6298","6302"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"体外诊断收入增70.16%","content_offset":["6298","6311"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+54.43%","10625","10632"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["体外诊断","6298","6302"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"医疗设备收入增33.80%","content_offset":["6326","6339"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["33.80%","6333","6339"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["医疗设备","6326","6330"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"医疗设备收入增33.80%","content_offset":["6326","6339"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+25.02%","13210","13217"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["医疗设备","6326","6330"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"高值耗材收入增9.75%","content_offset":["6353","6365"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["9.75%","6360","6365"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["高值耗材","6353","6357"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"高值耗材收入增9.75%","content_offset":["6353","6365"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-16.16%","13533","13540"],"indicator_element":{"时间":["2020年","7221","7226"],"行业":["高值耗材","6353","6357"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年医疗器械板块资产负债率稳步下降，为30.41%（-1.42%）","content_offset":["7413","7449"],"indicators":[{"indicator_name":"资产负债率","indicator_value":["30.41%","7435","7441"],"indicator_element":{"时间":["2020年","7413","7418"],"行业":["医疗器械","7418","7422"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年医疗器械板块资产负债率稳步下降，为30.41%（-1.42%）","content_offset":["7413","7449"],"indicators":[{"indicator_name":"资产负债率同比","indicator_value":["-1.42%","7442","7448"],"indicator_element":{"时间":["2020年","7413","7418"],"行业":["医疗器械","7418","7422"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年医疗器械板块毛利率58.11%（+5.78%）","content_offset":["7556","7584"],"indicators":[{"indicator_name":"毛利率","indicator_value":["58.11%","7570","7576"],"indicator_element":{"时间":["2020年","7556","7561"],"行业":["医疗器械","7561","7565"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年医疗器械板块毛利率58.11%（+5.78%）","content_offset":["7556","7584"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+5.78%","7577","7583"],"indicator_element":{"时间":["2020年","7556","7561"],"行业":["医疗器械","7561","7565"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率26.31%（+9.94%）","content_offset":["7585","7602"],"indicators":[{"indicator_name":"净利率","indicator_value":["26.31%","7588","7594"],"indicator_element":{"时间":["2020年","7509","7514"],"行业":["医疗器械","7503","7507"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率26.31%（+9.94%）","content_offset":["7585","7602"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+9.94%","7595","7601"],"indicator_element":{"时间":["2020年","7509","7514"],"行业":["医疗器械","7503","7507"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长135.89%（+119.35%）","content_offset":["1333","1362"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["135.89%","1345","1352"],"indicator_element":{"时间":["2020年","1333","1338"],"行业":["低值耗材","1263","1267"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长135.89%（+119.35%）","content_offset":["1333","1362"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+119.35%","1353","1361"],"indicator_element":{"时间":["2020年","1333","1338"],"行业":["低值耗材","1263","1267"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率55.22%（+16.01%）","content_offset":["8883","8901"],"indicators":[{"indicator_name":"毛利率","indicator_value":["55.22%","8886","8892"],"indicator_element":{"时间":["2020年","8784","8789"],"行业":["低值耗材","9109","9113"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率55.22%（+16.01%）","content_offset":["8883","8901"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+16.01%","8893","8900"],"indicator_element":{"时间":["2020年","8784","8789"],"行业":["低值耗材","9109","9113"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率30.64%（+18.70%）","content_offset":["8902","8920"],"indicators":[{"indicator_name":"净利率","indicator_value":["30.64%","8905","8911"],"indicator_element":{"时间":["2020年","9104","9109"],"行业":["低值耗材","9109","9113"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率30.64%（+18.70%）","content_offset":["8902","8920"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+18.70%","8912","8919"],"indicator_element":{"时间":["2020年","9104","9109"],"行业":["低值耗材","9109","9113"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率60.73%（+7.64%）","content_offset":["10702","10719"],"indicators":[{"indicator_name":"毛利率","indicator_value":["60.73%","10705","10711"],"indicator_element":{"时间":["2020年","10606","10611"],"行业":["体外诊断","10816","10820"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率60.73%（+7.64%）","content_offset":["10702","10719"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+7.64%","10712","10718"],"indicator_element":{"时间":["2020年","10606","10611"],"行业":["体外诊断","10816","10820"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率27.07%（+13.36%）","content_offset":["10720","10738"],"indicators":[{"indicator_name":"净利率","indicator_value":["27.07%","10723","10729"],"indicator_element":{"时间":["2020年","10811","10816"],"行业":["体外诊断","10816","10820"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率27.07%（+13.36%）","content_offset":["10720","10738"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+13.36%","10730","10737"],"indicator_element":{"时间":["2020年","10811","10816"],"行业":["体外诊断","10816","10820"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长33.80%（+25.02%）","content_offset":["2648","2675"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["33.80%","2660","2666"],"indicator_element":{"时间":["2020年","2648","2653"],"行业":["医疗设备","2619","2623"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长33.80%（+25.02%）","content_offset":["2648","2675"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["+25.02%","2667","2674"],"indicator_element":{"时间":["2020年","2648","2653"],"行业":["医疗设备","2619","2623"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率51.50%（3.63%）","content_offset":["13285","13301"],"indicators":[{"indicator_name":"毛利率","indicator_value":["51.50%","13288","13294"],"indicator_element":{"时间":["2020年","13191","13196"],"行业":["医疗设备","13435","13439"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率51.50%（3.63%）","content_offset":["13285","13301"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["3.63%","13295","13300"],"indicator_element":{"时间":["2020年","13191","13196"],"行业":["医疗设备","13435","13439"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率20.68%（+3.33%）","content_offset":["13302","13319"],"indicators":[{"indicator_name":"净利率","indicator_value":["20.68%","13305","13311"],"indicator_element":{"时间":["2020年","13430","13435"],"行业":["医疗设备","13435","13439"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率20.68%（+3.33%）","content_offset":["13302","13319"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+3.33%","13312","13318"],"indicator_element":{"时间":["2020年","13430","13435"],"行业":["医疗设备","13435","13439"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长9.75%（-16.16%）","content_offset":["3133","3159"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["9.75%","3145","3150"],"indicator_element":{"时间":["2020年","3133","3138"],"行业":["高值耗材","3110","3114"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2020年子版块收入增长9.75%（-16.16%）","content_offset":["3133","3159"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["-16.16%","3151","3158"],"indicator_element":{"时间":["2020年","3133","3138"],"行业":["高值耗材","3110","3114"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率69.76%（-2.26%）","content_offset":["13633","13650"],"indicators":[{"indicator_name":"毛利率","indicator_value":["69.76%","13636","13642"],"indicator_element":{"时间":["2020年","15449","15454"],"行业":["高值耗材","15454","15458"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"毛利率69.76%（-2.26%）","content_offset":["13633","13650"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["-2.26%","13643","13649"],"indicator_element":{"时间":["2020年","15449","15454"],"行业":["高值耗材","15454","15458"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率25.09%（+2.50%）","content_offset":["13651","13668"],"indicators":[{"indicator_name":"净利率","indicator_value":["25.09%","13654","13660"],"indicator_element":{"时间":["2020年","15449","15454"],"行业":["高值耗材","15454","15458"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率25.09%（+2.50%）","content_offset":["13651","13668"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+2.50%","13661","13667"],"indicator_element":{"时间":["2020年","15449","15454"],"行业":["高值耗材","15454","15458"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"各个子板块分化明显，低值耗材收入增201.32%","content_offset":["15708","15732"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["201.32%","15725","15732"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["低值耗材","15718","15722"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"体外诊断收入增149.54%","content_offset":["15747","15761"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["149.54%","15754","15761"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["体外诊断","15747","15751"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"高值耗材收入增63.21%","content_offset":["15776","15789"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["63.21%","15783","15789"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["高值耗材","15776","15780"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"医疗设备收入增45.83%","content_offset":["15803","15816"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["45.83%","15810","15816"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗设备","15803","15807"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1医疗器械板块资产负债率27.94%（-4.32%）","content_offset":["17659","17690"],"indicators":[{"indicator_name":"资产负债率","indicator_value":["27.94%","17676","17682"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17665","17669"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1医疗器械板块资产负债率27.94%（-4.32%）","content_offset":["17659","17690"],"indicators":[{"indicator_name":"资产负债率同比","indicator_value":["-4.32%","17683","17689"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17665","17669"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1医疗器械板块毛利率60.29%（+6.93%）","content_offset":["17808","17837"],"indicators":[{"indicator_name":"毛利率","indicator_value":["60.29%","17823","17829"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17814","17818"]},"indicator_supplement":{"属性":""}}]},{"id":"77","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"2021Q1医疗器械板块毛利率60.29%（+6.93%）","content_offset":["17808","17837"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+6.93%","17830","17836"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17814","17818"]},"indicator_supplement":{"属性":""}}]},{"id":"78","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率32.91%（+13.97%）","content_offset":["17838","17856"],"indicators":[{"indicator_name":"净利率","indicator_value":["32.91%","17841","17847"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17754","17758"]},"indicator_supplement":{"属性":""}}]},{"id":"79","source_document":"医疗器械板块2020、2021Q1总结：抗疫需求持续释放，医疗新基建带动新增长.pdf","content":"净利率32.91%（+13.97%）","content_offset":["17838","17856"],"indicators":[{"indicator_name":"净利率同比","indicator_value":["+13.97%","17848","17855"],"indicator_element":{"时间":["2021Q1年","-1","-1"],"行业":["医疗器械","17754","17758"]},"indicator_supplement":{"属性":""}}]}]}